Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas.

OBJECTIVE To determine the effectiveness of follow-up tests for signaling recurrences in patients with intermediate- and high-risk malignant melanomas treated with curative intention. DESIGN Retrospective analysis of prospectively collected data. SETTING North Central Cancer Treatment Group. PATIENTS A total of 261 patients with resected local (> or = 1.69 mm) and regional nodal malignant melanomas who were enrolled in a single prospective adjuvant trial were studied. All patients were scheduled to be followed up monthly for 2 months, then every 2 months for the first year, every 4 months the second year, every 6 months the next 3 years, and annually thereafter, with each visit consisting of a history, physical examination, complete blood cell count, blood chemistry panel, and a chest x-ray. RESULTS Of the 145 evaluable patients who developed recurrent melanomas, 99 patients (68%) developed symptoms that signaled the diagnosis of recurrent disease. Physical examination of asymptomatic patients led to the diagnosis of recurrent disease in 37 patients (26%). The other nine patients (6%) with recurrent disease had abnormal chest x-rays. Laboratory results were never a sole indicator of recurrent disease. CONCLUSION The majority of recurrences following resection of primary melanomas are discovered by history and/or physical examination despite the frequent use of other follow-up tests. The present data indicate that routine blood analyses and chest x-rays have limited value in the postoperative follow-up of patients with resected intermediate- and high-risk melanomas.

[1]  A Gafni,et al.  The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A Liberati,et al.  Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. , 1995, JAMA.

[3]  P. Brandani,et al.  First Recurrence Analysis of 840 Cutaneous Melanomas: A Proposal for a Follow-Up Schedule , 1994 .

[4]  M. Indelli,et al.  Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. , 1994, JAMA.

[5]  S. Ciatto,et al.  Intensive Diagnostic Follow-up After Treatment of Primary Breast Cancer: A Randomized Trial , 1994 .

[6]  C. Loprinzi It is now the age to define the appropriate follow-up of primary breast cancer patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Kopf,et al.  Follow-up recommendations for patients with stage I malignant melanoma. , 1994, The Journal of dermatologic surgery and oncology.

[8]  A. Sober,et al.  Guidelines of care for malignant melanoma , 1993 .

[9]  S. Padley,et al.  The efficacy of a single posteroanterior radiograph in the assessment of metastatic pulmonary melanoma. , 1993, The British journal of radiology.

[10]  A. Cohen,et al.  A case-control study of late recurrence of malignant melanoma. , 1992, American journal of surgery.

[11]  R. Dodge,et al.  The annual risk of melanoma progression. Implications for the concept of cure , 1992, Cancer.

[12]  E. R. Farmer,et al.  NIH Consensus conference. Diagnosis and treatment of early melanoma. , 1992, JAMA.

[13]  Gary S. Rogers,et al.  Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma , 1992 .

[14]  R. Moy,et al.  LACK OF PREDICTIVE FACTORS IN LATE RECURRENCE OF STAGE I MELANOMA , 1992, International journal of dermatology.

[15]  P. Kaufmann,et al.  [Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma]. , 1992, Aktuelle Radiologie.

[16]  N. Urban,et al.  A minimalist policy for breast cancer surveillance. , 1991, JAMA.

[17]  J. Matthews,et al.  Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. , 1990, Plastic and Reconstructive Surgery.

[18]  J. Thompson,et al.  Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. , 1988, Surgery, gynecology & obstetrics.

[19]  J. Hermans,et al.  An evaluation of routine follow‐up for detection of breast cancer recurrences , 1987, Journal of surgical oncology.

[20]  M. Cunningham,et al.  Preoperative and follow‐up procedures on patients with breast cancer , 1980, Cancer.

[21]  D. Winchester,et al.  Symptomatology as an indicator of recurrent or metastatic breast cancer , 1979, Cancer.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  V. L. Hall,et al.  Follow-up in stage I cutaneous malignant melanoma: an audit. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

[24]  L. Kalish,et al.  A retrospective study of earliest indicators of recurrence in patients on eastern cooperative oncology group adjuvant chemotherapy trials for breast cancer. A preliminary report , 1985, Cancer.

[25]  T. Brøyn,et al.  Evaluation of routine follow-up after surgery for breast carcinoma. , 1982, Acta chirurgica Scandinavica.